Considering that the publication from the February 2022 compounding hazard notify, FDA has become aware of expanding community curiosity in the use of sublingual and oral dosage types of compounded ketamine with the cure of psychiatric disorders. FDA understands that the opportunity to get this kind of products and solutions https://ketalinic.com/ketamine-r-isomer-s-isomer/